Preparation of rapidly disintegrating tablets of ondansetron hydrochloride by direct compression method
Keywords:
Composite index, Desirability function, Rapidly disintegrating tablets, Simplex lattice designAbstract
To make rapidly disintegrating tablets containing 8 mg ondansetron hydrochloride with suffi cient mechanical integrityas well as a pleasant taste, microcrystalline cellulose (MCC), lactose anhydrous, mannitol and croscarmellose wereformulated. Tablets were prepared by a direct compression method. Tablets properties such as tensile strength, disintegrationtime, wetting time and friability were determined. The two-factor spherical second order composite experimentaldesign was used for the preparation of preliminary batches and the desirability function was employed for theoptimization of preliminary batches. For preparation of the rapidly disintegrating tablets, simplex lattice design withconstraints on the proportion of excipients was utilized. In later design, tensile strength and disintegration time wereselected as dependent variables and concentration of microcrystalline cellulose, concentration of lactose anhydrous andconcentration of mannitol were selected as controlling factors. Mathematical equations and contour plots were usedto relate independent variables with tensile strength and disintegration time. Furthermore, the composite index which considers a positive or negative deviation from an ideal value was calculated for the optimization of the formulation.Contour plots of tensile strength and disintegration time were superimposed to fi nd out the optimized region at whichtablets with an acceptable crushing strength and disintegration time can be produced. The concept of similarity factorsf2 and Sd were used to prove similarity of dissolution in distilled water and simulated saliva (pH 6.8). Rapidly disintegratingtablets with durable structure and desirable taste could be prepared by selecting proper level of MCC, lactoseanhydrous, mannitol, croscarmellose and compression force.Downloads
References
Masaaki S, Kiji M, Yoshiyuki K, Maso K. Evaluation of rapidly disintegrating tablets prepared by a direct compression method. Pharm Dev Technol 1999; 6: 487-493.
Corveleyn S, Remon JP. Formulation and production of rapidly disintegrating tablets by lyophilisation using hydrochlorothiazide
as a model drug. Int J Pharm 1997; 152: 215–225.
Allen LV, Wang B, Davies, JD. Rapidly dissolving tablet. US Patent 5,807,576, September 15, 1998.
Roser BJ, Blair, J. Rapidly soluble oral solid dosage forms, methods of making same and compositions thereof. US Patent 5,762,96, June 9, 1998.
Sugimoto M, Matsubara K, Koida Y, Kobayashi M. The Preparation of rapidly disintegrating tablets in the mouth. Pharm Dev Technol 2001; 6: 487-493.
Bi Y, Yonezawa Y, Sunada H. Rapidly disintegrating tablets prepared by the wet compression method: mechanism and
optimization. J Pharm Sci 1999; 88: 1004 -1010.
Ito A, Sugihara M. Development of oral dosage form for elderly patients: use of agar as base of rapidly disintegrating Oral tablets. Chem Pharm Bull 1996; 44: 2132–2136.
Koizumi K, Watanabe Y, Morita K, Utoguchi N, Matsumoto M. New method of preparing high-porosity rapidly saliva soluble compressed tablets using mannitol with camphor, a subliming material. Int J Pharm 1997; 152: 127–131.
Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, Iida K. Preparation and evaluation of a compressed tablet rapidly
disintegrating in the oral cavity. Chem Pharm Bull 1996; 44: 2121–2127.
Bi YX, Sunada H, Yonezawa Y, Danjo K. Evaluation of rapidly disintegrating tablets prepared by a direct compression
method. Drug Dev Ind Pharm 1999; 25: 571-581.
Markham A, Sorkim EM. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993; 45: 931-952.
LeBourgeois JP, McKenna CJ, Coster B, Feyer P, Franzen L, Goedhals L, Marzecki Z, Souhami L, Stewart A, Tonnessen F, Haigh C, Mitchell T, Wilkinson JR, Graham E. Efficacy of an ondansetron orally disintegrating tablet: A novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis study group for the ondansetron orally disintegrating tablet in radiotherapy treatment.
Clin Oncol 1999; 11: 340-347.
Moore JW, Flanne HH. Mathematical comparison of dissolution profiles. Pharm Technol 1996; 20: 64-74.
U. S. department of health and human services. Food and drug administration, centre for drug evaluation and research.
Guidance for industry: Dissolution testing of immediate release solid dosage forms. August 1997.
Pillay V, Fassihi R. Evaluation and comparison of dissolution data derived from different modified release dosage forms: An alternative method. J Control Rel 1998; 55: 45-55.
Gohel MC, Panchal MK. Comparison of in vitro dissolution profiles using a novel, model-independent approach. Pharm Technol 2000; 24:92-102.
Gohel MC, Panchal MK. Novel use of similarity factor f2 and Sd for the development of diltiazem HCl modified-release tablets using a 32 factorial design. Drug Dev Ind Pharm 2002; 28: 77-87.
Lewis G, Mathieu D, Phan-Than-Luu R. Optimization: Pharmaceutical process optimization and validation. In Pharmaceutical Experimental Design, 1st Ed.; Swarbrick, James, Boylan, James C., Eds.; Marcel Dekker, Inc.: New York, 1999; Vol. 92, 265-276.
Paterakis PG, Korakianiti ES, Dallas PP, Rekkas DM. Evaluation and simultaneous optimization of some pellets characteristics using 33 factorial design and the desirability function. Int J Pharm 2002; 248: 51-60.
Fell JT, Newton JM. The tensile strength of lactose tablets. J Pharm Pharmacol 1968; 20: 657-659.
Schiermeier S, Schmidt PC. Fast dispersible ibuprofen tablets. Eur J Pharm Sci 2002; 15: 295-305.
Ferrari F, Bertoni M, Bonferoni CM, Rossi S, Caramella C, Bolhuis GK. Dissolution enhancement of an insoluble drug by physical mixture with a superdisintegrant: Optimization with a simplex lattice design. Pharm Dev Technol 1996; 1: 159-164.
Elkheshen S. Simplex lattice design for the optimization of the microencapsulation of a water soluble drug using poly (lactic acid) and poly (lactide co-glycolide) copolymer. J Microencapsul 1996; 13: 447-462.
Van Kamp HV, Bolhuis GK, Lerk CF. Optimization of a formulation for direct compression using a simplex lattice design. Pharm Weekbl Sci 1987; 9: 265-273.
Huisman R, Van Kamp HV, Weyland JW, Doornbos DA, Bolhuis, GK, Lerk CF. Development and optimization of pharmaceutical formulations using a simplex lattice design. Pharm Weekbl Sci 1984; 6: 185-194.
Piepel GF. Modeling methods for mixture-of-mixtures experiments applied to a tablet formulation problem. Pharm Dev Technol 1999; 4: 593-606.
Waaler PJ, Graffner C, Muller BW. Optimization of a matrix tablet formulation using a mixture design. Acta Pharm Nord 1992; 4: 9-16.
Dango K, Kimura H, Otuka A. Influence of punch velocity on the compressibility of granules. Drug Dev Ind Pharm 1996; 22: 933-942.
Nystrom C, Alderborn G, Duberg M, Karehill, PG. Bonding surface area and bonding mechanism-two important factors for the understanding of powder compatibility. Drug Dev Ind Pharm 1993; 19: 2143-2196.
Gissinger D, Stamm A. A comparative evaluation of the properties of some tablet disintegrants. Drug Dev Ind Pharm 1980; 6: 511-536.
Derringer G, Suich R. Simultaneous optimization of several responses variables. J Qual Technol 1980; 2: 214-219.
Bodea A, Leucata, SE. Optimization of hydrophilic matrix tablets using a D-optimal design. Int J Pharm 1997; 153: 247-255.
Wang YM, Sato H, Adachi I, Horikishi IJ. Optimization of the formulation design of chitosan microspheres containing cisplatin. Pharm Sci 1996; 85: 1204-1210.
Shigeo O, Toshihiko K, Yousuke M, Horoshima S, Kozo T, Nagai T. A new attempt to solve the scale up problem for granulation using response surface methodology. J Pharm Sci 1994; 83: 439-443.
Taylor MK, Ginsburg J, Hickey AJ, Gheyas F. Composite method to quantify powder flow as a screening method in early tablet or capsule formulation development. Pharm Sci Technol 2000;1: article 18. www.pharmscitech.com.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
